BioAge Labs Earnings Call Transcripts
Fiscal Year 2026
-
Phase I results for BGE-102 showed up to 86% CRP reduction and strong safety in obese subjects, with most patients reaching CRP below 2 mg/L. The drug demonstrated potent inhibition of IL-1β and IL-6, strong CNS/ocular penetration, and supports advancement into phase II cardiovascular and ophthalmology trials.
-
The company is advancing BGE-102, a novel NLRP3 inhibitor, into phase I and II trials for cardiovascular and ophthalmology indications, with promising early efficacy and safety data. Strong financials and sector interest support a robust pipeline, including APJ agonists for obesity.
-
The company presented strong phase I data for its oral NLRP3 inhibitor, showing best-in-class CRP reduction and favorable safety in obese patients. Key upcoming milestones include full phase I data, a three-month monotherapy trial, and a DME proof-of-concept study, with additional programs in obesity and ongoing pharma collaborations.
Fiscal Year 2025
-
First clinical data for a brain-penetrant NLRP3 inhibitor showed strong target engagement and safety, with upcoming studies in obese patients focusing on CRP reduction. The pipeline includes differentiated assets and a robust cash position, with plans for both independent and partnered development.
-
BioAge is advancing a unique NLRP3 inhibitor with strong brain penetration, focusing on cardiovascular and inflammatory benefits rather than weight loss, with phase I data expected by end of 2026. The APJ agonist program targets both oral and injectable obesity therapies, with IND filings planned for next year. Collaborations with Novartis and Lilly support early-stage discovery.
-
Aging-focused platform integrates vast longitudinal human data and AI to identify novel metabolic and neurodegenerative targets. Lead NLRP3 inhibitor for obesity is in phase 1, with key data expected by year-end and a robust pipeline of APJ agonists advancing toward IND filings. Over $310M in cash supports multi-year development and strategic partnerships.
-
The company leverages a proprietary platform to identify aging-related targets, advancing NLRP3 and APJ programs with strong preclinical and early clinical data. Key milestones include upcoming phase I and obesity trial readouts, with a robust cash position and strategic partnerships supporting pipeline growth.
-
The company is advancing aging-focused metabolic disease programs, with a brain-penetrant NLRP3 inhibitor entering clinical trials and a next-generation apelin program in development. Strategic collaborations with Novartis and Lilly support novel target discovery, while a strong cash position enables progress toward key clinical milestones.
Fiscal Year 2024
-
The company leverages large-scale human biobank data to identify metabolic disease targets, advancing azelaprag (an oral apelin agonist) in phase 2 trials for obesity and diabetes, with a strong safety profile and broad combination potential. A potent NLRP3 inhibitor and two early-stage assets expand the pipeline, while a $360M cash position supports operations through 2029.
-
Azelaprag, an oral energy expenditure agent, is being tested in combination with tirzepatide to achieve FDA-required incremental weight loss and superior tolerability, with top-line STRIDES data expected in Q3. The pipeline includes a potent NLRP3 inhibitor and robust financial runway into 2029.
-
Azelaprag, an oral apelin receptor agonist, is in phase II trials targeting metabolic disease, aiming for synergy with incretin therapies and improved weight loss. The pipeline includes a CNS-penetrant NLRP3 inhibitor and novel targets from aging cohort data. Lilly collaborates on trial design and holds a right of first negotiation.